Robert Tepper

Co-Founding Partner at Third Rock Ventures · Joined 2007

View Live Interactive Profile →

Biography

Robert Tepper is a co-founder of Third Rock Ventures, which the firm's site says he joined in 2007, and it describes him as a scientist with more than 30 years of experience building and operating R&D organizations in the biotech industry. He met co-founders Mark Levin and Kevin Starr while serving as president of R&D at Millennium Pharmaceuticals, and he also co-founded Cell Genesys/Abgenix. Third Rock lists Casma Therapeutics as his board position, and SEC filings record earlier directorships at Constellation Pharmaceuticals, bluebird bio, Kala Pharmaceuticals, Cerulean Pharmaceuticals, Jounce Therapeutics, Neon Therapeutics and Allena Pharmaceuticals. He holds an A.B. in biochemistry from Princeton University and an M.D. from Harvard Medical School.

Education

Previous Experience

Notable Investments

Constellation Pharmaceuticalsbluebird bioAllena PharmaceuticalsJounce TherapeuticsCasma Therapeutics

Board Seats

Career Timeline

2007
Co-founded Third Rock Ventures after serving as president of R&D at Millennium Pharmaceuticals.
2008
Became a director of Constellation Pharmaceuticals in April and its chief scientific officer through October 2009.
2010
Joined the bluebird bio board of directors, serving until 2015.
2011
Joined the board of Allena Pharmaceuticals at its $15 million Series A launch.
2013
Served as interim chief scientific officer on the founding management team of Jounce Therapeutics at its $47 million Series A.
2018
Served as interim chief scientific officer and board member at the launch of Casma Therapeutics with $58.5 million.

Sources & References

Third Rock Ventures - Robert Tepper ↗Casma Therapeutics - Our team ↗SEC DEF 14A - Constellation Pharmaceuticals 2020 ↗FierceBiotech - Allena Pharmaceuticals $15M Series A ↗FierceBiotech - Third Rock launches Jounce Therapeutics ↗BioSpace - Third Rock launches Casma Therapeutics ↗bluebird bio - completion of acquisition by Carlyle and SK Capital ↗